FDA Approves RILUZOLE — Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals today announced the FDA approval of its Abbreviated New Drug Application (ANDA091394) for generic riluzole, positioning the company to capitalize on the established market for this ALS treatment. This clearance expands Glenmark’s generic portfolio in the neurology segment and provides a new revenue stream to compete in the current Riluzole market.